Business Description

Kintara Therapeutics is a biopharmaceutical company focused on the development and commercialization of new cancer therapies.

VAL-083, is a "first-in-class" small molecule DNA-targeting agent that is currently being evaluated in a biomarker-driven Phase 2 clinical trial for the treatment of Unmethylated MGMT recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 in a Phase 2 trial as a therapy for front-line Unmethylated MGMT GBM and we may study other solid tumors, including ovarian cancer and pediatric CNS tumors.

REM-001 Therapy consists of three parts, a laser light source, a light delivery device and the drug REM-001 (collectively, REM-001 Therapy). REM-001 is a second generation photosensitizer drug that has undergone late stage clinical development, and which we believe possesses multiple advantages over earlier generation PDT compounds. Our lead indication for REM-001 Therapy is unresectable cutaneous metastatic breast cancer (CMBC), a disease that may affect individuals with advanced breast cancer and for which effective treatment options are limited. For this and similar cutaneous applications, the light delivery device is a simple and easy to use fiber optic wand that the physician employs to directly illuminate the tumor with light

Company Information

Address:
12707 High Bluff Drive
Suite 200
San Diego, CA, United States 92130

Telephone:
858-350-4364

Email:
info@kintara.com

Industry Classifications

Sector:
Healthcare

Industry:
Pharmaceuticals

NAICS:
HMO Medical Centers (621491)

SIC:
Hospital And Medical Service Plans (6324)